Teleflex Incorporated reported mixed results for the second quarter ended June 30, with revenue from continuing operations reaching $570.3 million, representing 28.9% growth compared to the prior year. However, GAAP diluted earnings per share declined to $0.96 from $1.54 year-over-year, reflecting the company’s ongoing transition following several major transactions.
The company’s core operating units demonstrated solid performance. Vascular revenue increased 9.0% to $246.3 million, while Surgical revenue grew 9.1% to $112.1 million, both exceeding currency-adjusted growth rates. Adjusted diluted earnings per share rose modestly to $1.76 from $1.73. Management executed significant balance sheet actions during the quarter, including closing the sale of its OEM business to Montagu and Kohlberg for $1.5 billion in cash, generating approximately $1.25 billion after taxes. Proceeds were used to repay a $700 million Term Loan A-2, and the company repurchased $250 million of stock at an average price of $130.85 per share during the quarter.
Management announced plans for an additional $250 million accelerated share repurchase commencing August 7, 2026, with $750 million remaining under existing buyback authorization. On the regulatory front, Teleflex obtained FDA approval in late July for EZPLAZ, the first freeze-dried plasma licensed in the United States. The company also advanced its Freesolve resorbable scaffold program, with four-year durability data and completed enrollment ahead of schedule in the BIOMAG-II trial.
Despite these positive developments, management reduced its full-year outlook across multiple metrics. Full-year GAAP revenue growth guidance was lowered to 13.40% to 14.40%, GAAP earnings per share guidance to $2.54 to $2.84, and pro forma adjusted constant currency revenue growth guidance to 3.50% to 4.50%. The guidance reduction primarily reflects slower-than-expected integration of the previously acquired Biotronik Vascular Intervention business, with pro forma adjusted constant currency Interventional revenue declining 1.0% on a core basis despite reported Interventional revenue jumping 86.1% from acquisition-related contributions.
Cash on hand declined to $316.9 million at quarter-end compared to $402.7 million at year-end 2025. Teleflex issued $500 million of new senior notes carrying a 5.875% coupon, replacing notes at 4.625%. Institutional investor activity increased, with 40 funds holding the stock during the quarter compared to 35 the prior quarter, while short interest remained elevated at 17.90% of the float. The stock’s forward price-to-earnings ratio stood at 12.39 as of September 4.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI